Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report - Study the Top 20 Companies With Products in the Early and Late Stage of Development
Posted on: Thursday, 13 September 2007, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c68370) has announced the addition of Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report to their offering.
"Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of diabetic neuropathy drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Content Outline:
RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
Diabetic Neuropathy Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Legend
--Top 20 companies in late stage Diabetic Neuropathy Projects
--Top 20 companies in early stage Diabetic Neuropathy Projects
Full Pipeline View
--Pre Clinical Pipeline View
--Phase II Pipeline View
For more information visit http://www.researchandmarkets.com/reports/c68370
Source: Business Wire
Related Articles
- Sangamo Reports Top-Line Data From Phase II Diabetic Neuropathy Trial
- Energy, Refining and Pipeline Construction Projects Push Wisconsin Industrial Development to $14.6 Billion, an Industrial Info News Alert
- Aegera Initiates Phase I Diabetic Neuropathy Study
- Current and Emerging Therapies Have No Advantage Over Pfizer's Lyrica in Their Effect on Patients' Quality of Life in the Treatment of Diabetic Neuropathy
- Heartland Oil and Gas Continues Production Enhancement and Well and Pipeline Expansion Projects in Texas and Kansas
- Sangamo BioSciences Initiates Phase 2 Clinical Trial of Novel Therapy for Diabetic Neuropathy
- Energy Transfer Partners, L.P. Announces Completion of First Phase of 42-Inch Pipeline Expansion Project
- Sangamo BioSciences Announces Plans for Phase 2 Clinical Trial of ZFP Therapeutic in Diabetic Neuropathy at JPMorgan Healthcare Conference
- Sangamo BioSciences Completes Enrollment and Treatment in Phase 1 Clinical Trial of ZFP Therapeutic in Diabetic Neuropathy
 |
 |
User Comments (0)
RSS Feeds